Vistagen Therapeutics, Inc. financial data

Symbol
VTGN on Nasdaq
Location
South San Francisco, CA
Fiscal year end
31 March
Latest financial report
10-Q - Q4 2025 - 12 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 571% % -61%
Debt-to-equity 22% % 127%
Return On Equity -110% % -128%
Return On Assets -90% % -105%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39,620,317 shares 37%
Entity Public Float $81,200,000 USD 30%
Common Stock, Value, Issued $40,000 USD 43%
Weighted Average Number of Shares Outstanding, Basic 42,234,405 shares 38%
Weighted Average Number of Shares Outstanding, Diluted 42,234,405 shares 38%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $52,023,000 USD 42%
General and Administrative Expense $18,665,000 USD 10%
Operating Income (Loss) $69,898,000 USD -32%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $67,046,000 USD -42%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $67,046,000 USD -42%
Earnings Per Share, Basic -1.9 USD/shares -104%
Earnings Per Share, Diluted -1.9 USD/shares -104%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $47,371,000 USD -37%
Cash, Cash Equivalents, and Short-term Investments $61,800,000 USD -30%
Assets, Current $63,245,000 USD -30%
Property, Plant and Equipment, Net $480,000 USD 12%
Operating Lease, Right-of-Use Asset $939,000 USD -36%
Other Assets, Noncurrent $392,000 USD -18%
Assets $65,056,000 USD -30%
Accounts Payable, Current $1,280,000 USD 23%
Employee-related Liabilities, Current $3,360,000 USD 108%
Accrued Liabilities, Current $9,254,000 USD 69%
Contract with Customer, Liability, Current $1,999,000 USD -20%
Liabilities, Current $13,529,000 USD 41%
Contract with Customer, Liability, Noncurrent $176,000 USD -61%
Operating Lease, Liability, Noncurrent $431,000 USD -61%
Liabilities $14,136,000 USD 26%
Accumulated Other Comprehensive Income (Loss), Net of Tax $13,000 USD 18%
Retained Earnings (Accumulated Deficit) $461,043,000 USD -17%
Stockholders' Equity Attributable to Parent $50,920,000 USD -37%
Liabilities and Equity $65,056,000 USD -30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $18,846,000 USD -73%
Net Cash Provided by (Used in) Financing Activities $1,488,000 USD 1591%
Net Cash Provided by (Used in) Investing Activities $788,000 USD 86%
Common Stock, Shares Authorized 325,000,000 shares 0%
Common Stock, Shares, Issued 39,624,839 shares 47%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $18,146,000 USD -12%
Interest Paid, Excluding Capitalized Interest, Operating Activities $6,000 USD
Deferred Tax Assets, Valuation Allowance $77,681,000 USD 28%
Deferred Tax Assets, Gross $77,705,000 USD 28%
Operating Lease, Liability $1,509,000 USD -29%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $67,044,000 USD -42%
Lessee, Operating Lease, Liability, to be Paid $1,679,000 USD -31%
Property, Plant and Equipment, Gross $1,880,000 USD 11%
Operating Lease, Liability, Current $617,000 USD 2.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two $753,000 USD 2.9%
Lessee, Operating Lease, Liability, to be Paid, Year One $672,000 USD -5.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.0854 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $170,000 USD -48%
Lessee, Operating Lease, Liability, to be Paid, Year Three $254,000 USD -66%
Deferred Tax Assets, Operating Loss Carryforwards $51,324,000 USD 10%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $2,399,000 USD -51%
Lessee, Operating Lease, Liability, to be Paid, Year Four $254,000 USD -66%
Additional Paid in Capital $515,878,000 USD 7.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $40,000 USD 18%
Deferred Tax Assets, Net of Valuation Allowance $24,000 USD 20%
Share-based Payment Arrangement, Expense $4,071,000 USD 5.1%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%